Preview

Сибутрамин: эффективность и безопасность применения в рутинной клинической практике

https://doi.org/10.14341/omet2015318-24

Полный текст:

Аннотация

В мае 2015 г. в Дублине состоялся 17-й Европейский конгресс по эндокринологии. В рамках секции ≪Ожирение≫ были представлены предварительные результаты наблюдательной программы ≪ПримаВера≫ в виде устного доклада. Данная статья представляет собой краткий обзор литературы, отражающий вопросы механизма действия, эффективности и безопасности сибутрамина, а также включает расширенный вариант основных положений доклада.

Об авторе

Татьяна Ивановна Романцова
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова МЗ РФ
Россия
д.м.н., профессор кафедры эндокринологии


Список литературы

1. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2014;384(9945):766-81. doi: 10.1016/s0140-6736(14)60460-8

2. Morton GJ, Meek TH, Schwartz MW. Neurobiology of food intake in health and disease. Nature Reviews Neuroscience. 2014;15(6):367-78. doi: 10.1038/nrn3745

3. Gautron L, Elmquist Joel K, Williams Kevin W. Neural Control of Energy Balance: Translating Circuits to Therapies. Cell. 2015;161(1):133-45. doi: 10.1016/j.cell.2015.02.023

4. Richard D. Cognitive and autonomic determinants of energy homeostasis in obesity. Nature Reviews Endocrinology. 2015;11(8):489-501. doi: 10.1038/nrendo.2015.103

5. Begg DP, Woods SC. The endocrinology of food intake. Nature Reviews Endocrinology. 2013;9(10):584-97. doi: 10.1038/nrendo.2013.136

6. Kenny Paul J. Reward Mechanisms in Obesity: New Insights and Future Directions. Neuron. 2011;69(4):664-79. doi: 10.1016/j.neuron.2011.02.016

7. Alonso-Alonso M, Woods SC, Pelchat M, Grigson PS, Stice E, Farooqi S, et al. Food reward system: current perspectives and future research needs. Nutrition Reviews. 2015;73(5):296-307. doi: 10.1093/nutrit/nuv002

8. Kringelbach ML. The pleasure of food: underlying brain mechanisms of eating and other pleasures. Flavour. 2015;4(1):20. doi: 10.1186/s13411-014-0029-2

9. Blier P. Rational site-directed pharmacotherapy for major depressive disorder. The International Journal of Neuropsychopharmacology. 2013;17(07):997-1008. doi: 10.1017/s1461145713000400

10. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2015;100(2):342-62. doi: 10.1210/jc.2014-3415

11. Jones BJ, Bloom SR. The New Era of Drug Therapy for Obesity: The Evidence and the Expectations. Drugs. 2015;75(9):935-45. doi: 10.1007/s40265-015-0410-1

12. Li Y-W, Langdon S, Pieschl R, Strong T, Wright RN, Rohrbach K, et al. Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats. European Journal of Pharmacology. 2014;737:47-56. doi: 10.1016/j.ejphar.2014.03.024

13. Khorassani FE, Misher A, Garris S. Past and present of antiobesity agents: Focus on monoamine modulators. American Journal of Health-System Pharmacy. 2015;72(9):697-706. doi: 10.2146/ajhp140034

14. Voigt J-P, Fink H. Serotonin controlling feeding and satiety. Behavioural brain research. 2015;277:14-31. 15. R. Araujo J, Martel F. Sibutramine Effects on Central Mechanisms Regulating Energy Homeostasis. Current Neuropharmacology. 2012;10(1):49-52. doi: 10.2174/157015912799362788

15. Kintscher U. Reuptake inhibitors of dopamine, noradrenaline, and serotonin. Appetite Control: Springer; 2012. p. 339-47.

16. Volkow ND, Wang G-J, Baler RD. Reward, dopamine and the control of food intake: implications for obesity. Trends in Cognitive Sciences. 2011;15(1):37-46. doi: 10.1016/j.tics.2010.11.001

17. van de Giessen E, McIlwrick S, Veltman D, van den Brink W, Booij J. Obesity an Addiction? Imaging of Neurotransmitter Systems in Obesity. 2014:641-56. doi: 10.1007/978-3-642-40384-2_27

18. Pratt WE, Connolly ME. Contrasting effects of systemic and central sibutramine administration on the intake of a palatable diet in the rat. Neuroscience Letters. 2010;484(1):30-4. doi: 10.1016/j.neulet.2010.08.011

19. Talbot PS, Bradley S, Clarke CP, Babalola KO, Philipp AW, Brown G, et al. Brain Serotonin Transporter Occupancy by Oral Sibutramine Dosed to Steady State: A PET Study Using 11C-DASB in Healthy Humans. Neuropsychopharmacology. 2009;35(3):741-51. doi: 10.1038/npp.2009.182

20. Fletcher PC, Napolitano A, Skeggs A, Miller SR, Delafont B, Cambridge VC, et al. Distinct Modulatory Effects of Satiety and Sibutramine on Brain Responses to Food Images in Humans: A Double Dissociation across Hypothalamus, Amygdala, and Ventral Striatum. Journal of Neuroscience. 2010;30(43):14346-55. doi: 10.1523/jneurosci.3323-10.2010

21. Chondronikola M, Volpi E, Borsheim E, Porter C, Annamalai P, Enerback S, et al. Brown Adipose Tissue Improves Whole-Body Glucose Homeostasis and Insulin Sensitivity in Humans. Diabetes. 2014;63(12):4089-99. doi: 10.2337/db14-0746

22. Betz MJ, Enerbäck S. Human Brown Adipose Tissue: What We Have Learned So Far. Diabetes. 2015;64(7):2352-60. doi: 10.2337/db15-0146

23. McGlashon Jacob M, Gorecki Michelle C, Kozlowski Amanda E, Thirnbeck Caitlin K, Markan Kathleen R, Leslie Kirstie L, et al. Central Serotonergic Neurons Activate and Recruit Thermogenic Brown and Beige Fat and Regulate Glucose and Lipid Homeostasis. Cell Metabolism. 2015;21(5):692-705. doi: 10.1016/j.cmet.2015.04.008

24. Connoley IP, Liu Y-L, Frost I, Reckless IP, Heal DJ, Stock MJ. Thermogenic effects of sibutramine and its metabolites. British Journal of Pharmacology. 1999;126(6):1487-95. doi: 10.1038/sj.bjp.0702446

25. Scheen AJ. Cardiovascular Risk-Benefit Profile of Sibutramine. American Journal Cardiovascular Drugs. 2010;10(5):321-34. doi: 10.2165/11584800-000000000-00000

26. Haslam D. Sibutramine: gone, but not forgotten. Practical Diabetes International. 2010;27(3):96-7. doi: 10.1002/pdi.1453

27. Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Vascular health and risk management. 2009;5:441.

28. Scheen AJ. Sibutramine on Cardiovascular Outcome. Diabetes Care. 2011;34(Supplement_2):S114-S9. doi: 10.2337/dc11-s205

29. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Current Medical Research and Opinion. 2005;21(3):457-66. doi: 10.1185/030079905x38132

30. James WPT, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, et al. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. New England Journal of Medicine. 2010;363(10):905-17. doi: 10.1056/NEJMoa1003114

31. Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes, Obesity and Metabolism. 2012;14(6):523-30. doi: 10.1111/j.1463-1326.2011.01554.x

32. Jordan J, Nilsson PM, Kotsis V, Olsen MH, Grassi G, Yumuk V, et al. Joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension. Journal of Hypertension. 2015;33(3):425-34. doi: 10.1097/hjh.0000000000000473

33. Toplak H, Woodward E, Yumuk V, Oppert J-M, Halford JCG, Frhbeck G. 2014 EASO Position Statement on the Use of Anti-Obesity Drugs. Obesity Facts. 2015:166-74. doi: 10.1159/000430801

34. Andersson C, van Gaal L, Caterson ID, Weeke P, James WPT, Couthino W, et al. Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high risk women and men with type 2 diabetes. Diabetologia. 2012;55(9):2348-55. doi: 10.1007/s00125-012-2584-3

35. Abbate A, Skak-Nielsen H, Torp-Pedersen C, Finer N, Caterson ID, Van Gaal L, et al. Uric Acid as a Risk Factor for Cardiovascular Disease and Mortality in Overweight/Obese Individuals. PLoS ONE. 2013;8(3):e59121. doi: 10.1371/journal.pone.0059121

36. Ghotbi AA, Kober L, Finer N, James WPT, Sharma AM, Caterson I, et al. Association of Hypoglycemic Treatment Regimens With Cardiovascular Outcomes in Overweight and Obese Subjects With Type 2 Diabetes: A substudy of the SCOUT trial. Diabetes Care. 2013;36(11):3746-53. doi: 10.2337/dc13-0027

37. Seimon RV, Espinoza D, Ivers L, Gebski V, Finer N, Legler UF, et al. Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. International Journal of Obesity. 2014;38(9):1165-71. doi: 10.1038/ijo.2014.2

38. Jørgensen ME, Torp-Pedersen C, Finer N, Caterson I, James WPT, Legler UF, et al. Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT trial. Nutrition, Metabolism and Cardiovascular Diseases. 2014;24(6):656-62. doi: 10.1016/j.numecd.2013.12.009

39. Seimon RV, Espinoza D, Finer N, James WPT, Legler UF, Coutinho W, et al. Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. International Journal of Obesity. 2014;39(5):849-57. doi: 10.1038/ijo.2014.211

40. Tyczynski JE, Oleske DM, Klingman D, Ferrufino CP, Lee WC. Safety Assessment of an Anti-Obesity Drug (Sibutramine). Drug Safety. 2012;35(8):629-44. doi: 10.1007/bf03261960

41. Hayes JF, Bhaskaran K, Batterham R, Smeeth L, Douglas I. The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom. International Journal of Obesity. 2015;39(9):1359-64. doi: 10.1038/ijo.2015.86

42. Бутрова С.А, Берковская М.А., Комшилова К.А. Опыт применения препарата Редуксин (сибутрамин) у больных с метаболическим синдромом. // Ожирение и метаболизм. – 2007. – №. 4. – С. 34-39. [Butrova SA, Berkovskaya MA, Komshilova KA. Opyt primeneniya preparata Reduksin (sibutramin) u bol'nykh s metabolicheskim sindromom. Obesity and metabolism. 2007;4(4):34-39] doi: 10.14341/2071-8713-5004.

43. Романцова Т.И., Полубояринова И.В. Роик О.В. Динамика состояния жировой ткани по данным MP-томографии у больных ожирением на фоне лечения Редуксином. // Ожирение и метаболизм. – 2012. – Т. 9. – №. 4. – С. 39-43. [Romantsova TI, Poluboyarinova IV, Roik OV. Dynamics of adipose tissue changes measured by MRI in obese patients during Reduxin treatment. Obesity and metabolism. 2012;9(4):39-43.] doi: 10.14341/2071-8713-5128.

44. А.М. Мкртумян, Е.В. Бирюкова, Н.В. Маркина, М.А. Гарбузова. Параметры эндотелиальной функции и инсулинорезистентности больных метаболическим синдромом до и после снижения массы тела. // Ожирение и метаболизм. – 2008. – №. 1. – C. 18-22. [Mkrtumyan AM, Biryukova EV, Markina NV, Garbuzova MA. Parameters of endothelial function and insulin resistance in patients with metabolic syndrome before and after weight loss. Obesity and metabolism. 2008;5(1):18-22.] doi:10.14341/omet2008118-22.

45. Аметов А. С. Эффективное лечение ожирения–путь борьбы с эпидемией Diabetus mellipidus. // Эффективная фармакотерапия. Медицинский совет. –2013. – №. 2. – С. 78-83. [Ametov A S. Effektivnoe lechenie ozhireniya–put' bor'by s epidemiey Diabetus mellipidus. Effektivnaya farmakoterapiya. Meditsinskiy sovet. 2013; 2:78-83].

46. Dedov I., Melnichenko G., Romantsova T., Zhuravleva M. Preliminary analysis of the PRIMAVERA Study: reduxine safety monitoring in patients with alimentary obesity. 17th European Congress of Endocrinology, 16–20 May 2015. Endocrine Abstracts, OC11.5

47. Sharma A. SCOUTing for Obesity Treatments. http:www.drsharma.ca/scouting-forobesity-treatments.


Для цитирования:


Романцова Т.И. Сибутрамин: эффективность и безопасность применения в рутинной клинической практике. Ожирение и метаболизм. 2015;12(3):18-24. https://doi.org/10.14341/omet2015318-24

For citation:


Romantsova T.I. Sibutramine: efficacy and safety of prescribing in routine clinical practice. Obesity and metabolism. 2015;12(3):18-24. (In Russ.) https://doi.org/10.14341/omet2015318-24

Просмотров: 41


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2071-8713 (Print)
ISSN 2306-5524 (Online)